Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax va...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Gaithersburg, United States

Rolltide2020 Sep. 14 at 1:37 PM

$EBS No reason to believe Q3 won’t bring more of the same.

0 · Reply

MoneyGroupLLC Sep. 14 at 12:45 AM

Enter: $EBS OCT 17 2025 $9 CALLS Buy in Price: $0.42 - $0.45 Take Profit: $0.51 Stop Bleeding: $0.37 ROI Potential: 21% Exit Within: 66 Minutes https://moneygroup.us/alerts

0 · Reply

zredpill Sep. 13 at 9:41 PM

$EBS

0 · Reply

zredpill Sep. 13 at 6:34 PM

$EBS st0nks go higher

1 · Reply

WinstonSmith33 Sep. 13 at 6:31 PM

$EBS WUT? Don't you understand that $EBS has no INTERNATIONAL rights for Ebanga?

1 · Reply

Rolltide2020 Sep. 13 at 5:38 PM

$EBS May have answered my own question.

0 · Reply

WinstonSmith33 Sep. 13 at 1:45 PM

$EBS Ridgeback Bio is a small biotech company and they needed a partner in several areas. "Under the terms of the contemplated collaboration, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga™, ensuring it remains available to patients in endemic countries free of charge through Ridgeback Bio’s compassionate use program." https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-and-ridgeback-biotherapeutics-enter

1 · Reply

Rolltide2020 Sep. 13 at 11:35 AM

$EBS Trying to figure out who would supply Europe with Ebanga. Our deal with Ridgeback appears to be for US and Canada only, while Ridgeback basically gives it away to impoverished nations and WHO….but WHO is not necessarily stockpiling for Europe…..who may want to stockpile like we do.

1 · Reply

Tradewind74 Sep. 13 at 10:00 AM

$EBS https://www.directorstalkinterviews.com/emergent-biosolutions-inc-ebs-stock-analysis-a-closer-look-at-a-potential-64-upside/4121216373

0 · Reply

ComradeKomisar Sep. 13 at 12:19 AM

$EBS "requirements" = PHEMCE

0 · Reply

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 2, 2025, 7:40 AM EDT - 12 days ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Aug 29, 2025, 8:05 AM EDT - 16 days ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 27, 2025, 8:01 AM EDT - 18 days ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 21, 2025, 8:45 AM EDT - 24 days ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 12, 2025, 12:46 PM EDT - 4 weeks ago

Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally

Aug 7, 2025, 7:31 PM EDT - 5 weeks ago

Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:15 PM EDT - 5 weeks ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Jul 28, 2025, 8:50 AM EDT - 6 weeks ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 6 weeks ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 15, 2025, 7:30 AM EDT - 2 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:45 PM EDT - 2 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 2, 2025, 4:05 PM EDT - 2 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jun 23, 2025, 8:05 AM EDT - 2 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 20, 2025, 2:25 PM EDT - 3 months ago

Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful

Jun 20, 2025, 8:13 AM EDT - 3 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 5, 2025, 7:00 AM EDT - 3 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

May 7, 2025, 10:01 PM EDT - 4 months ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 4 months ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 1, 2025, 5:07 PM EDT - 4 months ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Apr 22, 2025, 8:00 AM EDT - 5 months ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Mar 20, 2025, 4:30 PM EDT - 6 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 8:06 AM EDT - 6 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 19, 2025, 4:30 PM EDT - 6 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025, 8:00 AM EDT - 6 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 13, 2025, 8:29 AM EDT - 6 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 12, 2025, 8:00 AM EDT - 6 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 10, 2025, 9:14 AM EDT - 6 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 3, 2025, 7:58 PM EST - 6 months ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:23 PM EST - 6 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 8:55 AM EST - 7 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 7, 2025, 8:06 AM EST - 7 months ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Jan 16, 2025, 8:00 AM EST - 8 months ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Jan 14, 2025, 7:53 AM EST - 8 months ago

Emergent BioSolutions: Stock Is A Likely Winner In 2025

Jan 14, 2025, 7:30 AM EST - 8 months ago

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Jan 13, 2025, 9:27 AM EST - 8 months ago

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

Jan 8, 2025, 7:45 AM EST - 8 months ago

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 8, 2025, 7:30 AM EST - 8 months ago

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Dec 2, 2024, 5:49 PM EST - 10 months ago

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

SIGA

Nov 8, 2024, 9:25 AM EST - 11 months ago

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 7, 2024, 2:06 PM EST - 11 months ago

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Nov 6, 2024, 10:08 PM EST - 11 months ago

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:49 PM EST - 11 months ago

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Nov 4, 2024, 7:30 AM EST - 11 months ago

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

Oct 23, 2024, 7:30 AM EDT - 11 months ago

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

Oct 8, 2024, 5:32 PM EDT - 1 year ago

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Oct 4, 2024, 9:48 AM EDT - 1 year ago

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Sep 26, 2024, 8:05 AM EDT - 1 year ago

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Sep 25, 2024, 10:33 AM EDT - 1 year ago

Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines

Rolltide2020 Sep. 14 at 1:37 PM

$EBS No reason to believe Q3 won’t bring more of the same.

0 · Reply

MoneyGroupLLC Sep. 14 at 12:45 AM

Enter: $EBS OCT 17 2025 $9 CALLS Buy in Price: $0.42 - $0.45 Take Profit: $0.51 Stop Bleeding: $0.37 ROI Potential: 21% Exit Within: 66 Minutes https://moneygroup.us/alerts

0 · Reply

zredpill Sep. 13 at 9:41 PM

$EBS

0 · Reply

zredpill Sep. 13 at 6:34 PM

$EBS st0nks go higher

1 · Reply

WinstonSmith33 Sep. 13 at 6:31 PM

$EBS WUT? Don't you understand that $EBS has no INTERNATIONAL rights for Ebanga?

1 · Reply

Rolltide2020 Sep. 13 at 5:38 PM

$EBS May have answered my own question.

0 · Reply

WinstonSmith33 Sep. 13 at 1:45 PM

1 · Reply

Rolltide2020 Sep. 13 at 11:35 AM

1 · Reply

Tradewind74 Sep. 13 at 10:00 AM

$EBS https://www.directorstalkinterviews.com/emergent-biosolutions-inc-ebs-stock-analysis-a-closer-look-at-a-potential-64-upside/4121216373

0 · Reply

ComradeKomisar Sep. 13 at 12:19 AM

$EBS "requirements" = PHEMCE

0 · Reply

ComradeKomisar Sep. 13 at 12:05 AM

$EBS LMAO, did shorty raid the IBKR inventory bare again?

0 · Reply

WinstonSmith33 Sep. 12 at 10:42 PM

$EBS great news! "As of the date of this press release, eight patients have been treated with Ebanga™." Facts about Ebanga™: - Emergent Biosolutions has the rights only for the US and Canada - Ridgeback Bio has international rights - Emergent Biosolutions is responsible for production of the drug, also for Ridgeback Bio

2 · Reply

Rolltide2020 Sep. 12 at 10:29 PM

$EBS https://www.kxan.com/business/press-releases/cision/20250912FL72733/the-national-institute-of-biomedical-research-and-ridgeback-biotherapeutics-respond-to-16th-ebola-outbreak-in-the-democratic-republic-of-congo/

0 · Reply

zredpill Sep. 12 at 10:15 PM

$EBS I think they’ve done a good job in steering this ship.

1 · Reply

Kazoonova Sep. 12 at 9:25 PM

$EBS I wish there were an equivalent of the Razzies for the worst company board, because I’d nominate these guys in a heartbeat.

0 · Reply

ComradeKomisar Sep. 12 at 9:18 PM

$EBS Super effective

0 · Reply

WinstonSmith33 Sep. 12 at 8:05 PM

$EBS it looks that the management is effective - 13/15 red days - Tembexa order still unpublished

0 · Reply

KnuckleSandwich Sep. 12 at 7:48 PM

$EBS shorts can't cover more than 5K at a time without causing the price to surge... looking good for a strong close....also possibility of a positive news surprise on Monday!

1 · Reply

ComradeKomisar Sep. 12 at 6:52 PM

$EBS When they refi, and management decides to put its own foreskin in the game.

1 · Reply

Kazoonova Sep. 12 at 6:41 PM

$EBS When is this stock finally going to move up? It’s frustrating as hell watching all these other tickers go up, while this sits idle or declines.

0 · Reply

MoneyGroupLLC Sep. 12 at 6:40 PM

Enter: $EBS OCT 17 2025 $9 CALLS Buy in Price: $0.35 - $0.50 Take Profit: $0.43 Stop Bleeding: $0.31 ROI Potential: 24% Exit Within: 70 Minutes https://moneygroup.us/alerts

0 · Reply

ComradeKomisar Sep. 12 at 6:33 PM

$EBS Exit at $20 the bots say?

0 · Reply

Market Cap	434.28M
Revenue (ttm)	1.04B
Net Income (ttm)	-190.60M
EPS (ttm)	N/A
PE Ratio	3.59
Forward PE	N/A
Profit Margin	-18.26%
Debt to Equity Ratio	1.25

Volume	693,600
Avg Vol	1,196,302
Day's Range	N/A - N/A
Shares Out	53.35M
Stochastic %K	59%
Beta	2.04
Analysts	Sell
Price Target	$13.50